TW200533357A - 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases - Google Patents

2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases Download PDF

Info

Publication number
TW200533357A
TW200533357A TW094100533A TW94100533A TW200533357A TW 200533357 A TW200533357 A TW 200533357A TW 094100533 A TW094100533 A TW 094100533A TW 94100533 A TW94100533 A TW 94100533A TW 200533357 A TW200533357 A TW 200533357A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
substituted
heteroaryl
independently
Prior art date
Application number
TW094100533A
Other languages
English (en)
Chinese (zh)
Inventor
Paul E Fleming
Zhan Shi
shao-wu Chen
Jane F Schmidt
John C Reader
Neal D Hone
Jeffrey P Ciavarri
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200533357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of TW200533357A publication Critical patent/TW200533357A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094100533A 2004-01-08 2005-01-07 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases TW200533357A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
TW200533357A true TW200533357A (en) 2005-10-16

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094100533A TW200533357A (en) 2004-01-08 2005-01-07 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases

Country Status (18)

Country Link
US (2) US7732444B2 (enExample)
EP (2) EP2123647A1 (enExample)
JP (1) JP2007517895A (enExample)
AR (1) AR047185A1 (enExample)
AT (1) ATE437861T1 (enExample)
AU (1) AU2005204060A1 (enExample)
CA (1) CA2559888A1 (enExample)
CY (1) CY1109529T1 (enExample)
DE (1) DE602005015677D1 (enExample)
DK (1) DK1701944T3 (enExample)
ES (1) ES2330863T3 (enExample)
HR (1) HRP20090572T1 (enExample)
PL (1) PL1701944T3 (enExample)
PT (1) PT1701944E (enExample)
RS (1) RS51091B (enExample)
SI (1) SI1701944T1 (enExample)
TW (1) TW200533357A (enExample)
WO (1) WO2005066139A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
JP2009521488A (ja) * 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pkc−シータのインヒビターとして有益なピリミジン誘導体
WO2007107543A1 (en) * 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
AU2008236679B2 (en) * 2007-04-03 2013-11-28 Fmc Corporation Substituted benzene fungicides
HUE024877T2 (en) * 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
EP2169665B1 (en) 2008-09-25 2018-05-02 LG Electronics Inc. A method and an apparatus for processing a signal
EP2599494A1 (en) * 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2023104744A1 (en) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
JP2001526230A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CZ20012350A3 (cs) 1998-12-24 2001-09-12 Aventis Pharmaceuticals Products Inc. Substituované (aminoiminomethyl nebo aminomethyl) benzoheteroarylové sloučeniny
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2001000214A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
MXPA03008888A (es) * 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
MXPA04004166A (es) 2001-11-07 2004-07-08 Hoffmann La Roche Aminopirimidinas y piridinas.
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003106451A1 (en) * 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2004229392A1 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
ATE437861T1 (de) 2009-08-15
PT1701944E (pt) 2009-11-03
CY1109529T1 (el) 2014-08-13
CA2559888A1 (en) 2005-07-21
SI1701944T1 (sl) 2010-03-31
US8268822B2 (en) 2012-09-18
EP2123647A1 (en) 2009-11-25
US7732444B2 (en) 2010-06-08
WO2005066139A3 (en) 2005-10-13
US20060040968A1 (en) 2006-02-23
ES2330863T3 (es) 2009-12-16
WO2005066139A2 (en) 2005-07-21
US20110071134A1 (en) 2011-03-24
EP1701944A2 (en) 2006-09-20
RS51091B (sr) 2010-10-31
AR047185A1 (es) 2006-01-11
AU2005204060A1 (en) 2005-07-21
EP1701944B1 (en) 2009-07-29
PL1701944T3 (pl) 2010-01-29
DE602005015677D1 (de) 2009-09-10
JP2007517895A (ja) 2007-07-05
DK1701944T3 (da) 2009-11-09
HRP20090572T1 (hr) 2010-01-31

Similar Documents

Publication Publication Date Title
CN102271682B (zh) 用于治疗疼痛的p2x3受体拮抗剂
WO2022170802A1 (zh) 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
ES2445917T3 (es) Inhibidores de quinasa 1 reguladora de la señal de apoptosis
TW202115065A (zh) Kras突變蛋白抑制劑
CN103929961A (zh) 化合物及其治疗应用
TWI577677B (zh) 作爲ttx-s阻斷劑之吡咯並吡啶酮衍生物
TW201803854A (zh) 經胺取代之芳基或雜芳基化合物
TWI599562B (zh) 作爲ttx-s阻斷劑之醯胺衍生物
TW200815395A (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin D2 receptor antagonists
TW201211033A (en) 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
TW201024307A (en) Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
TW200813022A (en) Organic compounds
TW200825062A (en) Biaryl ether urea compounds
TW201240968A (en) Arylamide derivatives as TTX-S blockers
ES2330863T3 (es) 4-arilpiramidinas 2-(amino-sustituidas) y compuestos relacionados de utilidad para el tratamiento de enfermedades inflamatorias.
JPWO2010058846A1 (ja) 4,6−ジアミノニコチンアミド化合物
JP6278416B2 (ja) 置換4−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用
TW201609671A (zh) 經取代之二胺基嘧啶基化合物、其組合物及使用其之治療方法
USRE46630E1 (en) Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
CN107635404A (zh) 用于治疗疾病的mct4抑制剂
CN103539784A (zh) 杂环苯甲酰胺类化合物、药用组合物及其应用
TWI601726B (zh) 吡唑並吡啶衍生物作爲ttx-s阻斷劑
CN116685585A (zh) 一种高活性的hpk1激酶抑制剂
TWI429630B (zh) 升糖素受體調節劑
TW202519514A (zh) 新穎化合物(一)